Professor Lessof replied that he realized much more could be said on this question and he was grateful to Dr Hayward, who had been associated with this work, for his comments. He agreed that iron might well have immunological effects. Dr B Mornington ( Wellcome Foundation, London) said Professor Lessof stated that immune deficiency caused autoimmune diseases such as systemic lupus; this seemed rather paradoxical, particularly in view of the value of immunosuppressive therapy in systemic lupus. Professor Lessof replied that he did not say immune deficiency caused autoimmune reactions although, in immune deficiency states, there were many examples of situations where autoimmune reactions became more common. It had been speculated that these reactions might be a reflexion of a failure to eliminate antigen and an indication of immune deficiency. This was the challenging concept which he wished to repeat. He thought, in practice, that until there was a better approach the clinical empirical use of drugs for systemic lupus would have to continue as before. If attention was paid to these associations of immune deficiency with increased evidence of autoimmunity, one merely became more conscious of the failings of present therapeutic philosophy. An unidentified speaker said that he was stimulated by Professor Lessof's comments on iron deficiency and how this could not always be equated with hemoglobin. He was at present looking at cytochrome mitochondria and he immediately thought ofiron deficiency being involved in cytochrome synthesis. One of the aspects of these general-features of deficiency perhaps might be looked at with respect to energy requirement. It was known that in all these reactions there was a quite stringent requirement for ATP for example, and one immediately thought of mitochondria. Possibly this was a common factor, and perhaps cytochrome synthesis and the proteins involved in the respiratory chain were behind it. However, he did not know of any examples which could be tied down to a deficiency in cytochromes or in respiratory activity, but he did not know that there were examples in other organisms where deficiency, for example in cytochrome C, could lead to susceptibility to antibiotics and that aplastic anxmias, for instance, might result, which could be related back to a deficiency in cytochrome C. Dr W J Irvine wished to comment on the paradox between immunodeficiency and autoimmune disease. One of the attractive hypotheses was that the T-cells might have a physiologically controlling influence on what the B-cells making the antibodies might do, so that if there was an immunodeficiency of T-cells there might be an over-activity of the other cellular components of the immune system. Hence if the Tcells in an experimental animal were removed by thymectomy and there was subsequent sublethal irradiation, not only antinuclear factors but experimental thyroiditis would be produced, or, at least, thyroiditis would spontaneously appear. This at least gave an idea of how an immune deficiency might link up with an autoimmune disease. Professor Ziff said that there was some evidence for the point of view that the T-cell produced an immuno-depressive substance which kept the B-cell from acting. Talal had recently injected NZB mice with BCG. In so doing he had been able to eliminate any nuclear response in these animals. Professor Coombs wished to mention one more factor in the discussion of immunodeficiency in autoantibody formation. One of the main causes associated with autoantibody formation was infection. With immunodeficiency there was more infection and therefore more likelihood of initiating an autoantibody formation. An unidentified speaker said he had intended to make that point and add one comment. In the so-called autoimmune diseases which had been studied carefully in man and in experimental animals, in the majority of instances where the primary causes of the immunological event was known, this turned out to be an infection. For example, nearly all types of spontaneous nephritis in animal experiments could be shown to be due to an infection. In man, in the majority of instances in which the cause was known it was also due to an infection, although, of course, the cause was usually not known. Professor Lessof: I would agree heartily with that. The rheumatoid synovial membrane has perivascular mononuclear infiltrates in the sublining layer. When examined in the electron microscope, these infiltrates show a unique pattern of infiltration (Kobayashi et al. 1973) . Some consist almost entirely of small lymphocytes ( Fig I) and others mainly of plasma cells (Fig 2) . Transitional areas made up of both lymphocytes and plasma cells cells are also present. Both the lymphocyte-rich and the plasma-cell-rich areas contain blastic cells. Some of these have aggregated polyribosomes and nucleoli but no endoplasmic reticulum and have the appearance of lymphoblasts. Others contain endoplasmic reticulum and have the appearance of plasmablasts. It is of interest that the transitional areas are particularly rich in blast cells (Ishikawa & Ziff, unpublished data): the transitional areas contained 27.1 % blast cells in comparison with approximately 5 % of these cells in the other areas. The distribution of macrophages is also of interest. The smallest number of macrophages was present in the lymphocyte-rich areas, 3.5 %. The plasma-cell-rich areas contained 10.7%. The transitional areas, which were, as mentioned, also rich in blast cells, contained the highest proportion of macrophages, 18.4 %.
B-and T-Lymphocytes in
The presence of lymphocyte-rich and plasmacell-rich areas in similar perivascular distribution, usually around venules, suggests that the lymphocytes are largely transformed to plasma cells and that they are, therefore, mainly of the B-lymphocyte variety. The fact that the transitional areas contain large numbers of blast cells, many without endoplasmic reticulum, suggests that T-lymphoblasts are present in these areas. This would be consistent with the large numbers of macrophages also seen in this region and raises the possibility that a macrophage migration inhibitory factor (MIF) may be liberated in their proximity. Such an interpretation of the electron microscope findings would imply a role for cellular immunity in rheumatoid synovitis. However, it is likely, in view of the relatively large numbers of plasma cells observed, that the major variety of lymphocyte present is the B-lymphocyte. This would be consistent with the large amount of immunoglobulin synthesized by the rhematoid synovium (Smiley et al. 1968 ) and with the evidence for the synthesis of rheumatoid factor in this tissue (Munthe & Natvig 1972) .
More direct evidence has been obtained in this laboratory by Stastny et al. (1973) for the participation of cellular immunity in the rheumatoid inflammatory reaction by the demonstration in rheumatoid synovial effusions of a substance with migration inhibitory factor activity. Rheumatoid synovial fluid was brought to pH 5.0 or, in some experiments, treated with hyaluronidase to remove the hyaluronic acid. The supernatant was then chromatographed on Sephadex G-200. The fractions obtained were assayed for macrophage migration inhibitory activity. It was observed that migration inhibitory activity was associated with the third peak, which is eluted with the albumin marker. This is the peak in which MIF may be expected to be eluted on Sephadex G-200. Twenty-two rheumatoid joint fluids and 15 synovial effusions from patients with osteoarthritis have been studied after Sephadex fractionation. In 16 of the rheumatoid fluids (73 %), there was significant macrophage migration inhibitory activity. Only 3 of 15 fluids (20%) from patients with osteoarthritis were active. The difference between the two groups was highly significant. However, the presence of migration inhibitory factor was not limited to rheumatoid arthritis. The third peak from Sephadex G-200 of fluids from other patients with chronic synovitis showed MIF activity, including one case of psoriatic arthritis, one of three with Reiter's syndrome and one of two with gonococcal arthritis. Two effusions from patients with villonodular synovitis and three gouty effusions were inactive.
In addition to these studies with synovial effusions, rheumatoid synovial tissues obtained at surgical synovectomy were also examined for the presence of MIF activity (Stastny et al. 1973) . The tissue was cut into small pieces and incubated for forty-eight hours. The materials released into the supernatant tissue culture medium were then studied using similar techniques. Nine of 11 such supernatants had migration inhibitory activity. Four were fractionated on Sephadex G-200 and the activity was observed to be associated with materials eluting in the third peak. These observations suggest production of a migration inhibitory factor by rheumatoid synovial tissue.
In view of the suggestive evidence for a cellular immune process in rheumatoid synovitis, indicating participtation of T-lymphocytes, and the known evidence for the synthesis of immunoglobulin (Smiley et al. 1968 ) and rheumatoid factor in this tissue (Munthe & Natvig 1972) , efforts were made to explore the effect of an immunosuppressive agent, cyclophosphamide, on the circulating T-and B-lymphocytes of the blood. Cyclophosphamide, an alkylating agent which has a cytotoxic effect on lymphocytes, has shown beneficial effects in about 75 % of patients treated (Fosdick et al. 1968 ). In the studies to be described, a group of 9 patients were treated for a period of 10 months at an average dosage of 121 mg daily (Hurd & Ziff 1973) . A significant decrease in joint score indicating clinical improvement was noted after two months of treatment. A number of laboratory parameters were studied in these patients to determine which might be significantly related to the clinical improvement. No significant decreases in the mean values of sensitized sheep cell agglutination titre for rheumatoid factor, erythrocyte sedimentation rate, C3 complement level, and total gamma globulin occurred. IgA, IgG and IgM levels fell significantly only after prolonged treatment.
Among the circulating white blood cells, polymorphonuclear cell counts were unchanged over the ten-month period. Similarly, large and medium lymphocyte counts were not depressed. Only the small lymphocytes and monocytes fell in an impressive manner. The decreases in these cell counts were statistically significant after two months, the time of first significant decrease in joint score.
In view of the impressive fall in small lymphocyte count on cyclophosphamide, the levels of B-and T-lymphocytes were determined in these patients (Hurd et al. 1973 ). B-lymphocytes were measured by fluorescent antibody staining for membrane-bound immunoglobulin and T-lymphocytes by the spontaneous rosette test using sheep erythrocytes. Correction for IgG-coated monocytes was made on the basis of phagocytosis of latex particles. The patient groups examined were: 20 normal females; 14 patients with systemic lupus erythematosus (SLE), receiving either no treatment or prednisolone alone; 8 patients with SLE treated with cyclophosphamide for a mean duration of 41 weeks; 6 patients with other connective tissue diseases (4 with scleroderma, 2 with rheumatoid arthritis) on conservative therapy; and 7 patients with other connective tissue diseases (3 with scleroderma, 3 with rheumatoid arthritis, 1 with severe discoid lupus erythematosus) who received cyclophosphamide for a mean duration of 21 weeks.
The absolute counts of the B-lymphocytes, measured as the sum of IgG-, IgAand IgMstaining cells, were significantly reduced in non-cyclophosphamide-treated SLE patients in comparison with the normal controls. However, further significant reduction was observed in the SLE patients receiving cyclophosphamide. Cyclophosphamide also significantly reduced the Blymphocytes in the group of patients with other connective tissue diseases. The T-lymphocytes, as measured by spontaneous rosette formation, were also found to be decreased in the SLE group prior to cyclophosphamide therapy. Their counts were, in fact, so low that treatment with cyclophosphamide did not appear to reduce them further in a significant manner. However, in the patients with the other connective tissue diseases who received cyclophosphamide, the T-lymphocyte counts were significantly reduced in comparison with those who did not receive this drug.
In several patients, T-lymphocytes and Blymphocytes were followed serially during cyclophosphamide treatment. It was observed that both the T-and B-lymphocytes decreased in more or less parallel fashion. Significant decreases could be observed as early as two weeks after onset of treatment, i.e. at a time prior to clinical improvement. Since both T-and B-lymphocytes were reduced by cyclophosphamide, it appears likely that both cellular and humoral immunity may be affected by this agent.
Summary
Electron microscopic observations suggested that both B-and T-lymphocytes are present in rheumatoid synovial membrane. Lymphoblasts and plasmablasts were present. The blastic cells were most prominent in transitional areas containing lymphocytes, plasma cells and relatively high concentrations of macrophages.
In rheumatoid synovial effusions, an agent with macrophage migration inhibitory activity was demonstrated. This agent was also present in supernatants obtained by incubation of rheumatoid synovial membrane for several days. These findings suggest the occurrence of a cellular immune response in addition to antibody formation in this tissue.
Cyclophosphamide treatment reduced both T-and B-lymphocytes in the circulating blood, demonstrating that this drug is effective against both the cellular and humoral types of immune response in the rheumatoid synovium. The Chairman (Sir Peter Medawar) wished to ask a question about the administration of cyclophosphamide. If in rheumatoid arthritis the synovium became a sort of ectopic lymph node, as Professor Ziff seemed to suggest, would not the natural place for injecting the immunosuppressive agents be into the joint cavity? Professor Ziff replied that this had been done with thiotepa and nitrogen mustard with not too dramatic effect. To be effective these drugs would have to exert their antiproliferative and cytotoxic effects on lymphocytes in the sublining layer of the synovium. It seemed doubtful that intermittent injections would maintain sufficient levels in this tissue layer to exert a consistent and persistent effect on lymphocyte function.
A Questioner asked Professor Ziff to reconcile his observations on systemic lupus erythematosus with the fairly general idea that in this disease T-cell function was poor and B-cell function good, as evidenced, for example, by hyperglobulinmmia and capacity to raise large amounts of antibodies to various antigens. Professor Ziff said that if the questioner meant that T-cell function was poor in the sense that there was a decrease in cellular immunity he thought the evidence was growing that this was so, and that the low percentage of spontaneous sheep cell rosette-forming cells which he described in SLE was consistent with this.
Asked if the antibody response had been high, Professor Ziff replied that in many chronic inflammatory diseases he thought antibody response was high. With Dr Hugo Jasin he had noted, upon incubating the circulating lymphocytes of patients with SLE and measuring the amount of immunoglobulin produced, that they produced much more than controls. In other words, in SLE there were increased numbers of differentiated B cells circulating in the blood. Dr G Panayi (Guy's Hospital Medical School, London) said that Professor Duthie's Unit in Edinburgh had been interested in the mechanism of macrophage giantcell formation in the inflamed synovial membrane of rheumatoid arthritis. It had been shown that synovial fluid from rheumatoid effusions could promote the formation of giant-cells by monocytes from peripheral human blood. This activity was predominantly present in the 4S fraction on Sephadex gel filtrationthe fraction where lymphokine activity was normally present. They believed that giant-cell formation wvas a reflection, in part, ofa delayed hypersensitivity reaction in the inflamed joint and was brought about by factor or factors which activated macrophages and could also cause macrophage aggregation. Similar activity was present in effusions from other inflammatory polyarthritides such as Still's disease and ankylosing spondylitis. These results would indicate that irrespective of the initiating event in such diseases there was a final common pathway in promoting inflammation amongst which might be included cellmediated immunity with the release of lymphokines or lymphokine-like factors. Professor Ziff said that among the many lymphokines there was a macrophage migration inhibitory factor. He did not know whether there was a giant-cellforming factor, but there might well be. Did Dr Panayi think there was a lymphokine which might function as a giant-cell-forming factor? Dr Panayi replied that it was known from the work of Weiss, in a rather different system (culturing chicken blood in plasma clots), that the life history of a macrophage was to be activated and then to form epithelioid cells, giant cells and then die. Giant cell formation might be the result of this kind of situation where macrophages were being activated by lymphokines. Macrophage-aggregating factor was a lymphokine and this might be one factor promoting macrophage fusion, with the formation of giant cells. The existence of a separate giant-cell-forming factor could not be excluded. Dr A Florin-Christensen asked why Professor Ziff chose heterologous gamma globulin instead of homologous ones when following up the patients being treated. How did he explain 'no changes' in the antigammaglobulin factor titres while all immunoglobulin levels decreased with the treatment ? Professor Ziff replied that the sensitized sheep cell agglutination method was a classical test which had been used for rheumatoid factor titres since it was discovered in 1940. It depended on a cross-reaction between human and rabbit gamma globulin. The fall in immunoglobulin levels in patients with rheumatoid arthritis on cylcophosphamide had been no greater than the fall in rheumatoid factor titre. Professor Brent (St Mary's Hospital Medical School, London) asked what was known about the antigens which provoked the reponse in rheumatoid arthritis?
Secondly, had Professor Ziff examined the histology ofjoints after cyclophosphamide treatment? Professor Ziff supposed that rheumatoid arthritis must start with an antigen, presumably an exogenous one which stimulated a large amount of IgC and rheumatoid factor synthesis in the synovium. He thought that the antigen might well be a virus of unknown identity, if one did not want to fall back on an autoimmune response as the primary trigger. Autoimmunity apparently played a role secondarily by the formation of anti-IgC and immune complexes based on this antibody which were phlogogenic, but he thought this autoimmune response needed an exogenous trigger.
He had not examined the histology of joints after cyclophosphamide treatment. Dr Hohn said that, secondly, Professor Ziff gave the total number of B-and T-cells. Did he pick up 100% lymphocytes by summation of B-cells and T-cells or were there cells which remained unidentified by these tests ? Professor Ziff replied that they did not pick up total numbers by percentage; possibly their method for spontaneous rosette formation, whereby it was hoped that three or four cells would attach themselves before it was called a rosette, reduced the numbers. It depended a great deal on how strict was the definition of a rosette; some people would accept one or two attached cells, while others would require more. He thought it was preferable in these studies not to calculate percentages because they could be distorted by a fall of one cell type, B or T, preferentially to the other, but to give the absolute numbers so that one knew the actual number of cells one was dealing with. Dr Holm agreed that one should give the total numbers. Was 100 % obtained? Professor Ziff said it was not; 65-85% of the total were accounted for. Dr Holm thought there was a risk in methods which did not pick up 100% of lymphocytes. For example, if cyclophosphamide was interfering with T rosette formation there might be a false lower number in treated patients because the test did not work, not because the T-cell number was decreased. Professor Ziff said that in such a situation percentages and absolute numbers would both be in error.
A Questioner asked if Professor Ziff could elaborate on the significance of the lymphokines which he found. He showed that these biological activities were present and then suggested a little enigmatically that these lymphokines might be found at any site of chronic inflammation. Could he say whether he thought that the finding of these lymphokines should be associated with a site of chronic inflammation or whether he was suggesting that chronic inflammation was always based upon a T-cell activation. Professor Ziff replied that lymphokines were polypeptides of a definite size and biological activity. He suggested that in chronic inflammatory sites digestion of protein might occur, with the production of polypeptides of appropriate size and biological activity. These would not in this case represent proof of delayed hypersensitivity. If that objection were not raised the finding of lymphokine activity in chronic inflammation would suggest that a T-cell response was involved.
